A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine

被引：2

作者：

Ripamonti, Diego ^{[1
,5
]}

Rusconi, Stefano ^{[2
,3
]}

Zazzi, Maurizio ^{[4
]}

机构：

[1] ASST Papa Giovanni XXIII, Infect Dis Unit, Bergamo, Italy

[2] Univ Milan, Legnano Gen Hosp, ASST Ovest Milanese, Infect Dis Unit, Milan, Italy

[3] Univ Milan, DIBIC Luigi Sacco, Milan, Italy

[4] Univ Siena, Dept Med Biotechnol, Siena, Italy

[5] ASST Papa Giovanni XXIII, Bergamo, Italy

来源：

AIDS | 2024年 / 38卷 / 02期

关键词：

HIV;

D O I：

10.1097/QAD.0000000000003760

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：263 / 265

页数：3

共 23 条

[11] Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort [J].

Maggiolo, Franco ;

Valenti, Daniela ;

Teocchi, Rodolfo ;

Comi, Laura ;

Di Filippo, Elisa ;

Rizzi, Marco .

JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2022, 21

[12] HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program [J].

Masich, Anne M. ;

Gomes, Denese ;

Higginson, Robert T. ;

Morgan, Zara ;

Nixon, Daniel ;

Tran, Melissa ;

Winthrop, Elizabeth ;

Fulco, Patricia P. .

AIDS, 2023, 37 (10) :1641-1642

[13] Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks [J].

Murray, Miranda ;

Antela, Antonio ;

Mills, Anthony ;

Huang, Jenny ;

Jaeger, Hans ;

Bernal, Enrique ;

Lombaard, Johan ;

Katner, Harold ;

Walmsley, Sharon ;

Khuong-Josses, Marie-Aude ;

Hudson, Krischan ;

Dorey, David ;

Griffith, Sandy ;

Spreen, William ;

Vanveggel, Simon ;

Shaefer, Mark ;

Margolis, David ;

Chounta, Vasiliki .

AIDS AND BEHAVIOR, 2020, 24 (12) :3533-3544

[14] Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir plus Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure [J].

Orkin, Chloe ;

Schapiro, Jonathan M. ;

Perno, Carlo F. ;

Kuritzkes, Daniel R. ;

Patel, Parul ;

DeMoor, Rebecca ;

Dorey, David ;

Wang, Yongwei ;

Han, Kelong ;

Van Eygen, Veerle ;

Crauwels, Herta ;

Ford, Susan L. ;

Latham, Christine L. ;

St. Clair, Marty ;

Polli, Joseph W. ;

Vanveggel, Simon ;

Vandermeulen, Kati ;

D'Amico, Ronald ;

Garges, Harmony P. ;

Zolopa, Andrew ;

Spreen, William R. ;

van Wyk, Jean ;

Cutrell, Amy G. .

CLINICAL INFECTIOUS DISEASES, 2023, 77 (10) :1423-1431

[15] Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial [J].

Osiyemi, Olayemi ;

De Wit, Stephane ;

Ajana, Faiza ;

Bisshop, Fiona ;

Portilla, Joaquin ;

Routy, Jean-Pierre ;

Wyen, Christoph ;

Ait-Khaled, Mounir ;

Leone, Peter ;

Pappa, Keith A. ;

Wang, Ruolan ;

Wright, Jonathan ;

George, Nisha ;

Wynne, Brian ;

Aboud, Michael ;

van Wyk, Jean ;

Smith, Kimberly Y. .

CLINICAL INFECTIOUS DISEASES, 2022, 75 (06) :975-986

[16] Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial [J].

Ramgopal, Moti N. ;

Castagna, Antonella ;

Cazanave, Charles ;

Diaz-Brito, Vicens ;

Dretler, Robin ;

Oka, Shinichi ;

Osiyemi, Olayemi ;

Walmsley, Sharon ;

Sims, James ;

Di Perri, Giovanni ;

Sutton, Kenneth ;

Sutherland-Phillips, Denise ;

Berni, Alessandro ;

Latham, Christine L. ;

Zhang, Feifan ;

D'Amico, Ronald ;

Bernaldez, Miguel Pascual ;

Van Solingen-Ristea, Rodica ;

Van Eygen, Veerle ;

Patel, Parul ;

Chounta, Vasiliki ;

Spreen, William R. ;

Garges, Harmony P. ;

Smith, Kimberly ;

van Wyk, Jean .

LANCET HIV, 2023, 10 (09) :E566-E577

[17] Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir [J].

Rhee, Soo-Yon ;

Parkin, Neil ;

Harrigan, P. Richard ;

Holmes, Susan ;

Shafer, Robert W. .

ANTIVIRAL RESEARCH, 2022, 208

[18] The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions [J].

Rusconi, Stefano ;

Santoro, Maria M. ;

Capetti, Amedeo F. ;

Gianotti, Nicola ;

Zazzi, Maurizio .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (03)

[19]

Scutari R, 2023, ICAR

[20]

Scutari R, 2023, ICAR

← 1 2 3 →